Treatment Group Treatment Group Treatment Group Treatment Group
Durability of Response Total (N=76) Sirolimus (N=51) Vincristine (N=25) *p-value
Persistent disease 3 months from start of therapy, n (%) 2/76 (2.6%) 2/51 (3.9%) 0/25 (0%) >0.9
Persistent disease 6 months from start of therapy, n (%) 5/76 (6.6%) 5/51 (9.8%) 0/25 (0%) 0.2
Time to persistent disease from start of systemic therapy (days), median [IQR] 566 [365.9-1493] 414 [352-1148] 1486 [1067-1902] 0.2
Persistent disease requiring change in treatment agent, n (%) 9/76 (11.8%) 7/51 (13.7%) 2/25 (8%) 0.7
Persistent disease requiring continuation of current therapy, n (%) 14/76 (18.4%) 14/51 (27.5%) 0/25 (0%) 0.003
Recurrent disease 3 months from start of therapy, n (%) 2/76 (2.6%) 1/51 (2%) 1/25 (4%) >0.9
Recurrent disease 6 months from start of therapy, n (%) 1/76 (1.3%) 0/51 (0%) 1/25 (4%) 0.3
Time to recurrent disease from start of systemic therapy (days), median [IQR] 825.5 [372.3-1273.5] 1024 [583-1318] 379 [231-913] 0.3
Recurrent disease requiring change in treatment agent, n (%) 8/76 (10.5%) 5/51 (9.8%) 3/25 (12%) >0.9
Recurrent disease requiring re-initiation of prior therapy, n (%) 13/76 (17.1%) 11/51 (21.6%) 2/25 (8%) 0.2
Progressive disease 3 months from start of therapy, n (%) 1/76 (1.3%) 1/51 (2%) 0/25 (0%) >0.9
Progressive disease 6 months from start of therapy, n (%) 1/76 (1.3%) 1/51 (2%) 0/25 (0%) >0.9
Time to progressive disease from start of systemic therapy (days), median [IQR] 730 [395-885] 730 [562.5-1215] 553 [387-719] 0.8
Progressive disease requiring change in treatment agent, n (%) 3/76 (3.9%) 2/51 (3.9%) 1/25 (4%) >0.9
Progressive disease requiring re-initiation of prior therapy, n (%) 3/76 (3.9%) 2/51 (3.9%) 1/25 (4%) >0.9